Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal

GlobeNewswireApr 30 19:05

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in

BenzingaApr 22 19:38

Clearside Biomedical(CLSD.US) Director Buys US$129.66K in Common Stock

$Clearside Biomedical(CLSD.US)$ Director Gibney Anthony S purchased 100K shares of common stock on Apr 17, 18, 2024 at an average price of $1.3 for a total value of $129.66K.Source: Announcement What

Futu NewsApr 19 22:27

Press Release: Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to Its Board of Directors

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors - Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A wi

Dow JonesApr 16 19:05

Needham: Reiterates Clearside Biomedical (CLSD.US) rating, adjusted from buy to buy rating, target price $4.00.

Needham: Reiterates Clearside Biomedical (CLSD.US) rating, adjusted from buy to buy rating, target price $4.00.

Zhitong FinanceApr 11 18:01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)

TipRanksApr 11 17:50